Table 4.
Results of changing drug and testing protocol for anti-malarial drug distribution compared to a strategy of three rounds mass test and treat with artemether-lumefantrine at 72 % coverage per round of all ages of the population with 60 days between rounds
| % Change in median parasite prevalence (IQR) compared to baseline strategy, by pre-intervention mean parasite prevalence | |||||||
|---|---|---|---|---|---|---|---|
| % | Baseline intervention strategy | MTAT with DHAP | MTAT with DHAP + ivermectin | MDA with DHAP | MDA with DHAP + ivermectin | MDA with DHAP + SLD primaquine | MDA with DHAP + ivermectin + SLD primaquine |
| <10 | MTAT with AL, 72 % coverage, 60 day frequency between rounds, targeting all ages | 0.56 (−25.5, 52.4) |
4.5 (−28.0, 50.10 |
−7.6 (−32.2, 25.5) |
−3.6 (−30.5, 33.9) |
−17.1 (−35.0, 33.6) |
−12.3 (−32.8, 32.2) |
| 10–24 | −7.2 (−27.0, 15.3) |
−8.8 (−28.6, 16.3) |
−33.0
(−56.0, −16.0) |
−33.5
(−48.1, −9.5) |
−35.7
(−56.7, −10.8) |
−39.0
(−53.5, −10.8) |
|
| >24 | −0.2 (−11.9, 11.4) |
−1.1 (−13.6, 9.7) |
−44.1
(−53.6, −21.9) |
−43.6
(−56.1, −33.7) |
−36.4
(−55.4, −27.2) |
−40.4
(−55.1, −28.4) |
|
Italics indicate results that perform better than the baseline strategy